Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung Cancer.
Michael SkwarskiDaniel R McGowanElizabeth BelcherFrancesco Di ChiaraDionisios StavrouliasMark McColeJennifer L DerhamKwun-Ye ChuEugene TeohJagat ChauhanDawn O'ReillyBenjamin Howell Lole HarrisPhilip S MacklinJoshua A BullMarcus GreenGonzalo Rodriguez-BerrigueteRemko PrevoLisa K FolkesLeticia CampoPetra FerenczPaula L CroalHelen FlightCathy QiJane HolmesJames P B O'ConnorFergus V GleesonW Gillies McKennaAdrian L HarrisDaniel BulteFrancesca M BuffaRuth E MacphersonGeoff S HigginsPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
This is the first clinical evidence that targeting tumor mitochondrial metabolism can reduce hypoxia and produce relevant antitumor effects at the mRNA level. Repurposing atovaquone for this purpose may improve treatment outcomes for NSCLC.